Amylyx hires new CMO from Ultragenyx; Eliot Forster is back as a CEO after F-star sale
→ With Amylyx Pharmaceuticals’ ALS drug in full commercial swing, the Massachusetts startup has found a replacement for its chief medical officer. Camille Bedrosian will join the company from Ultragenyx, taking the place of Patrick Yeramian, whose retirement was announced in December 2022. Bedrosian has made a career in rare disease drug development, having previously worked not only at Ultragenyx but also Alexion, where she was also the CMO. The rare disease angle is one Amylyx aims to focus on as the FDA reconsiders how it views ALS and potential new regulatory and trial access bills make their way through Congress.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
